Comprehensive Biomarker Discovery with the 54-Plex Panel

Traditional biomarker discovery follows a fragmented workflow: screen by ELISA one analyte at a time (consuming mL of sample), or use broad but analytically noisy bead-based panels, then validate hits on a different platform — introducing cross-platform variability at every transition. The 54-Plex consolidates this into a single platform, single sample, single run: the same ECL detection chemistry that validates your hits is the same chemistry that discovered them.

Sub-Panel Structure and Biological Rationale

The 54 analytes are not an arbitrary list — they are organized into seven functionally coherent sub-panels, each targeting a specific aspect of human biology. This modular architecture means the 54-Plex can be deployed as a complete discovery panel, or individual sub-panels can be run independently for focused follow-up — all on the same instrument platform with the same detection technology.

  • Proinflammatory Panel 1 (10 analytes): IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNF-α — the core cytokine panel for Th1/Th2/inflammatory balance
  • Cytokine Panel 1 (10 analytes): GM-CSF, IL-1α, IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF-β, VEGF-A — extended cytokine and growth factor coverage
  • Chemokine Panel 1 (10 analytes): Eotaxin, Eotaxin-3, IL-8, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, TARC — immune cell trafficking and chemotaxis
  • Angiogenesis Panel 1 (7 analytes): FGF (basic), PlGF, Tie-2, VEGF-A, VEGF-C, VEGF-D, VEGFR-1/Flt-1 — vascular remodeling and angiogenic signaling
  • TH17 Panel 1 (7 analytes): IL-17A, IL-21, IL-22, IL-23, IL-27, IL-31, MIP-3α — autoimmune and inflammatory TH17 axis
  • Cytokine Panel 2 (8 analytes): IL-17A/F, IL-17B/C/D, IL-1RA, IL-3, IL-9, TSLP — additional IL-17 family members and regulatory cytokines
  • Vascular Injury Panel 2 (4 analytes): CRP, SAA, sICAM-1, sVCAM-1 — acute-phase proteins and endothelial activation markers

Research Applications Across Disease Areas

Because the 54-Plex spans cytokine, chemokine, angiogenic, and vascular injury pathways simultaneously, it is one of the few biomarker discovery tools applicable across multiple therapeutic areas without panel switching:

  • Autoimmune & inflammatory diseases — SLE, RA, IBD, psoriasis: TH17 cytokines (IL-17A, IL-21, IL-22, IL-23) + proinflammatory cytokines + chemokines + acute-phase proteins in a single run
  • Cardiovascular & metabolic disease — CRP, SAA, sICAM-1, sVCAM-1 + angiogenesis panel (VEGF family, Tie-2, PlGF) + inflammatory cytokines for cardiometabolic risk stratification research
  • Immuno-oncology — 54 analytes capturing the tumor-immune interface: checkpoint-related cytokines, chemokines driving T-cell infiltration, angiogenic factors reflecting tumor vasculature, and acute-phase proteins indicating systemic inflammatory response
  • Infectious disease & vaccine research — broad cytokine/chemokine profiling captures the full innate-to-adaptive immune response cascade, from early IFN responses through T-cell polarization to memory signatures
  • Respiratory disease — TH2 cytokines (IL-4, IL-5, IL-13), eosinophil-associated chemokines (Eotaxin family), and TSLP — key mediators of Type 2 airway inflammation — all quantified simultaneously

The 54-Plex has been used in published peer-reviewed research including a 2024 study in Communications Medicine (Nature) applying the panel to biomarker discovery in diverse disease contexts. DOI: 10.1038/s43856-024-00474-2